|Bid||69.00 x 1000|
|Ask||69.25 x 1000|
|Day's Range||68.47 - 74.52|
|52 Week Range||11.24 - 152.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. The Company is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. ET.
Karuna stock has nearly septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test. The drug proved itself over five weeks.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
Stock futures: Can software rejoin the market rally as Paylocity breaks out? ServiceNow added to gains late. Apple, Karuna Therapeutics, Roku and ZTO Express moved on news too.
Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial of its schizophrenia treatment met its primary endpoint. Trading volume ballooned to 6.5 million shares, compared with the full-day average of about 70,000 shares. The company said its KarXT port the treatment of acute psychosis in schizophrenia patients demonstrated a "statistically significant and clinically meaningful" reduction in total positive and negative syndrome scale (PANSS) score compared with a placebo. KarXT was also well tolerated. "With this information, and following our anticipated end-of-Phase 2 meeting with the FDA in the second quarter of 2020, we will work to initiate a Phase 3 clinical trial of KarXT in patients with schizophrenia by the end of 2020," said Chief Medical Officer Stephen Brannan. The stock, which went public on June 28 at an initial-public-offering price of $16, has nearly tripled (up 182%) over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 5.5% and the S&P 500 has rallied 7.9%.
President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.
Karuna Therapeutics, Inc. (NASDAQ: KRTX ) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna focuses on developing novel therapies to address disabling ...
Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week. The IPO Terms Boston, Massachusetts-based Karuna Therapeutics, ...